Brief: Relief Therapeutics, Acer Therapeutics Report EC Orphan Drug Tag For ACER-001
12/08/2022 13:46
Aug 12 (Reuters) - Acer Therapeutics Inc ACER.O :
* RELIEF THERAPEUTICS AND ACER THERAPEUTICS ANNOUNCE THAT
EUROPEAN
COMMISSION HAS GRANTED ORPHAN DRUG DESIGNATION FOR ACER-001 IN
MAPLE SYRUP URINE DISEASE
Source text for Eikon: ID:nGNX9BKS5F
Further company coverage: ACER.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31